The Past, Present, and Future of Rare Disease Trials · 12-year UK...
Transcript of The Past, Present, and Future of Rare Disease Trials · 12-year UK...
![Page 1: The Past, Present, and Future of Rare Disease Trials · 12-year UK epidemiologicstudyofPIND,147differentdiagnoseswererecordedin 1114 of 2636patients](https://reader036.fdocuments.us/reader036/viewer/2022062602/5ed3ee7ab385103868573c1b/html5/thumbnails/1.jpg)
Infinite Possibilities: The Past, Present, and Future of Rare
Disease Therapeutics
Erika Fullwood Augustine, MD, MS
Robert J. Joynt Associate Professor of Neurology and Pediatrics
Associate Director, Center for Health + Technology
University of Rochester Medical Center
![Page 2: The Past, Present, and Future of Rare Disease Trials · 12-year UK epidemiologicstudyofPIND,147differentdiagnoseswererecordedin 1114 of 2636patients](https://reader036.fdocuments.us/reader036/viewer/2022062602/5ed3ee7ab385103868573c1b/html5/thumbnails/2.jpg)
![Page 3: The Past, Present, and Future of Rare Disease Trials · 12-year UK epidemiologicstudyofPIND,147differentdiagnoseswererecordedin 1114 of 2636patients](https://reader036.fdocuments.us/reader036/viewer/2022062602/5ed3ee7ab385103868573c1b/html5/thumbnails/3.jpg)
PAST
![Page 4: The Past, Present, and Future of Rare Disease Trials · 12-year UK epidemiologicstudyofPIND,147differentdiagnoseswererecordedin 1114 of 2636patients](https://reader036.fdocuments.us/reader036/viewer/2022062602/5ed3ee7ab385103868573c1b/html5/thumbnails/4.jpg)
12-year UKepidemiologic study of PIND, 147 different diagnoses were recorded in 1114 of 2636patients <16 years.
Verity C, et al. Arch Dis Child. 2010;95:361–364.
Diagnoses in children with progressive intellectual & neurologic deterioration (PIND)
Top 10 diagnoses in n=1819 children diagnosed with PIND in the UK 1997 - 2017.
Verity C, et al. Arch Dis Child. 2018
![Page 5: The Past, Present, and Future of Rare Disease Trials · 12-year UK epidemiologicstudyofPIND,147differentdiagnoseswererecordedin 1114 of 2636patients](https://reader036.fdocuments.us/reader036/viewer/2022062602/5ed3ee7ab385103868573c1b/html5/thumbnails/5.jpg)
Otto Christian Stengel (1826)
1st description of NCL
5
Stengel O. Report about a strange illness in four siblings in the vicinity of Røros [in Norwegian]. Hager P, Andersen T, trans. Eyr. 1826;1:347-352
Neuronal Ceroid Lipofuscinosis – Historical Perspective
![Page 6: The Past, Present, and Future of Rare Disease Trials · 12-year UK epidemiologicstudyofPIND,147differentdiagnoseswererecordedin 1114 of 2636patients](https://reader036.fdocuments.us/reader036/viewer/2022062602/5ed3ee7ab385103868573c1b/html5/thumbnails/6.jpg)
• Otto Christian Stengel (1826) – 1st description of NCL
• Batten (1903) – 1st report with pathology
• Vogt (1905), Spielmeyer (1905)
• Jansky (1908), Bielschowsky (1913) – reported a similar late-infantile onset disorder
• Kufs (1925) – reported a similar adult-onset disorder
• Haltia and Santavuori (1973) – described infantile-onset form
6Mink JW, et al. J Child Neurol 2013;28(9):1101-1105.
Neuronal Ceroid Lipofuscinosis – Historical Perspective
![Page 7: The Past, Present, and Future of Rare Disease Trials · 12-year UK epidemiologicstudyofPIND,147differentdiagnoseswererecordedin 1114 of 2636patients](https://reader036.fdocuments.us/reader036/viewer/2022062602/5ed3ee7ab385103868573c1b/html5/thumbnails/7.jpg)
Neuronal Ceroid Lipofuscinoses• Group of lysosomal storage diseases• Most prevalent neurodegenerative disorder of
childhood, 1:12,500• Unifying clinicopathologic features
- clinical symptoms- progressive neuronal loss- autofluorescent storage material
Haltia et al, Biochim et Biophys Acta 2006; 1762: 850–856
A: GRODsB: curvilinear profilesC: fingerprint patternsD: rectilinear profiles
Neuronal Ceroid Lipofuscinoses
![Page 8: The Past, Present, and Future of Rare Disease Trials · 12-year UK epidemiologicstudyofPIND,147differentdiagnoseswererecordedin 1114 of 2636patients](https://reader036.fdocuments.us/reader036/viewer/2022062602/5ed3ee7ab385103868573c1b/html5/thumbnails/8.jpg)
Augustine, et al. J Child Neurol 2013
NCL type Intervention Indication
Sample
size
Duration of
follow-up Conclusion Reference
JNCL Antioxidants Disease modification 74 6-18 yrs Inconclusive
Santavuori
1988
JNCL
Polyunsaturated fatty
acids Disease modification 5 1 yr Inconclusive Bennett 1988
LINCL,
JNCL Antioxidants Disease modification 3 0.5 - 1.75 yrs Inconclusive Naidu 1988
JNCL
Polyunsaturated fatty
acids Disease modification 6 4 -7 yrs Possibly effective Bennett 1994
JNCL Antioxidants Disease modification 43 8 yrs Possibly effective
Santavuori
1989
JNCL Antioxidants Disease modification 46 Unknown Possibly effective
Santavuori
1977
JNCL Antioxidants Disease modification 125 4 - 11 yrs Partially effective
Santavuori
1985
JNCL Antiparkinsonian drugs Parkinsonism 8
11-13 wks per
treatment
period x3 Ineffective
Zweije-
Hofman 1982
Randomized, placebo controlled, clinical trial
Case Series
Open label, single group clinical trials
Open label, historical control clinical trial
Open label, parallel group clinical trials
![Page 9: The Past, Present, and Future of Rare Disease Trials · 12-year UK epidemiologicstudyofPIND,147differentdiagnoseswererecordedin 1114 of 2636patients](https://reader036.fdocuments.us/reader036/viewer/2022062602/5ed3ee7ab385103868573c1b/html5/thumbnails/9.jpg)
PASTDescribing phenomenology, grouping characteristics, and linking to pathological findings
![Page 10: The Past, Present, and Future of Rare Disease Trials · 12-year UK epidemiologicstudyofPIND,147differentdiagnoseswererecordedin 1114 of 2636patients](https://reader036.fdocuments.us/reader036/viewer/2022062602/5ed3ee7ab385103868573c1b/html5/thumbnails/10.jpg)
PRESENT
![Page 11: The Past, Present, and Future of Rare Disease Trials · 12-year UK epidemiologicstudyofPIND,147differentdiagnoseswererecordedin 1114 of 2636patients](https://reader036.fdocuments.us/reader036/viewer/2022062602/5ed3ee7ab385103868573c1b/html5/thumbnails/11.jpg)
Diagnostic Odyssey
• Average 5-7 years to diagnosis
• 40% have misdiagnosis
• Up to 50% never achieve a specific disease diagnosis
![Page 12: The Past, Present, and Future of Rare Disease Trials · 12-year UK epidemiologicstudyofPIND,147differentdiagnoseswererecordedin 1114 of 2636patients](https://reader036.fdocuments.us/reader036/viewer/2022062602/5ed3ee7ab385103868573c1b/html5/thumbnails/12.jpg)
otsegoknights.org
Genetic discoveries
![Page 13: The Past, Present, and Future of Rare Disease Trials · 12-year UK epidemiologicstudyofPIND,147differentdiagnoseswererecordedin 1114 of 2636patients](https://reader036.fdocuments.us/reader036/viewer/2022062602/5ed3ee7ab385103868573c1b/html5/thumbnails/13.jpg)
The Orphan Drug Act (ODA)
• Decade prior to 1983 – only ~1 drug/year independently developed by pharmaceutical sponsors
• Legislation needed to promote rare disease drug development
• The Orphan Drug Act signed into law on Jan. 4, 1983
![Page 14: The Past, Present, and Future of Rare Disease Trials · 12-year UK epidemiologicstudyofPIND,147differentdiagnoseswererecordedin 1114 of 2636patients](https://reader036.fdocuments.us/reader036/viewer/2022062602/5ed3ee7ab385103868573c1b/html5/thumbnails/14.jpg)
Development for CNS disorders is rising
JACC. Volume 64, Issue 5, August 2014
![Page 15: The Past, Present, and Future of Rare Disease Trials · 12-year UK epidemiologicstudyofPIND,147differentdiagnoseswererecordedin 1114 of 2636patients](https://reader036.fdocuments.us/reader036/viewer/2022062602/5ed3ee7ab385103868573c1b/html5/thumbnails/15.jpg)
http://www.raredr.com/news/orphan-approval; Clinical Development Success Rates 2006-2015, BIO
Higher rates of success for rare diseases
![Page 16: The Past, Present, and Future of Rare Disease Trials · 12-year UK epidemiologicstudyofPIND,147differentdiagnoseswererecordedin 1114 of 2636patients](https://reader036.fdocuments.us/reader036/viewer/2022062602/5ed3ee7ab385103868573c1b/html5/thumbnails/16.jpg)
The Orphan Drug Act has had strong impact and rare disease approvals are on the rise
Source: FDA Law Blog
Orphan Product Approvals
![Page 17: The Past, Present, and Future of Rare Disease Trials · 12-year UK epidemiologicstudyofPIND,147differentdiagnoseswererecordedin 1114 of 2636patients](https://reader036.fdocuments.us/reader036/viewer/2022062602/5ed3ee7ab385103868573c1b/html5/thumbnails/17.jpg)
![Page 18: The Past, Present, and Future of Rare Disease Trials · 12-year UK epidemiologicstudyofPIND,147differentdiagnoseswererecordedin 1114 of 2636patients](https://reader036.fdocuments.us/reader036/viewer/2022062602/5ed3ee7ab385103868573c1b/html5/thumbnails/18.jpg)
otsegoknights.org
Genetic discoveries
![Page 19: The Past, Present, and Future of Rare Disease Trials · 12-year UK epidemiologicstudyofPIND,147differentdiagnoseswererecordedin 1114 of 2636patients](https://reader036.fdocuments.us/reader036/viewer/2022062602/5ed3ee7ab385103868573c1b/html5/thumbnails/19.jpg)
The # of recognized unique mutations and unique variants is risingDC Koboldt, et al. Cell 2013; 155(1):27-38
OMIM Phenotypes for which the Molecular Basis is Known (2007 & 2013)
Impact of the Next Generation Sequencing Era
![Page 20: The Past, Present, and Future of Rare Disease Trials · 12-year UK epidemiologicstudyofPIND,147differentdiagnoseswererecordedin 1114 of 2636patients](https://reader036.fdocuments.us/reader036/viewer/2022062602/5ed3ee7ab385103868573c1b/html5/thumbnails/20.jpg)
Timeline of gene discovery in epilepsy
Mol Syndromol 2016;7:172–181
![Page 21: The Past, Present, and Future of Rare Disease Trials · 12-year UK epidemiologicstudyofPIND,147differentdiagnoseswererecordedin 1114 of 2636patients](https://reader036.fdocuments.us/reader036/viewer/2022062602/5ed3ee7ab385103868573c1b/html5/thumbnails/21.jpg)
Gene Age at Onset Chromosome Protein Ultrastructure
CLN1 InfantileLate infantile, juvenile, and adult
1p32 PPT1 Granular Osmophilic deposits (GRODS)
CLN2 Late infantileJuvenile
11p15 TPP1 Curvilinear profiles
CLN3 Juvenile 16p12 Transmembrane protein (lysosomal)
Fingerprint profiles
CLN4 (DNAJC5)
Adult (AD) (Parry) 20q13.33 Cysteine string protein Rectilinear profiles
CLN5 Late infantile (Finnish variant)
13q22 Soluble protein (lysosomal) Rectilinear profiles, Curvilinear profiles, Fingerprint profiles
CLN6 Late InfantileAdult (Kufs)
15q21 Transmembrane protein (endoplasmic reticulum)
Rectilinear profiles, Curvilinear profiles, Fingerprint profiles
CLN7 Late Infantile (Turkish variant)
4q28 MFSD8, membrane protein (lysosomal)
Fingerprint profiles
CLN8 Late infantile (Northern epilepsy)
8q23 Transmembrane protein (endoplasmic reticulum)
Curvilinear profiles
CLN10 Congenital 11p15 Cathepsin D GRODS
![Page 22: The Past, Present, and Future of Rare Disease Trials · 12-year UK epidemiologicstudyofPIND,147differentdiagnoseswererecordedin 1114 of 2636patients](https://reader036.fdocuments.us/reader036/viewer/2022062602/5ed3ee7ab385103868573c1b/html5/thumbnails/22.jpg)
New Classification of NCL Disorders
According to GENES and CLINICAL TYPEDesignation of disease
Genetic type Clinical type (age of onset)Mutated gene
Williams RE, Mole SE. Neurology. 2012;79:183-191.
• Infantile (6–24 months)
• Late infantile (2–5 years)
• Juvenile (5–7 years)
• Adult
• CLNX disease• CLNX
Example: CLN2 disease, late infantile
Current NCL Classification
![Page 23: The Past, Present, and Future of Rare Disease Trials · 12-year UK epidemiologicstudyofPIND,147differentdiagnoseswererecordedin 1114 of 2636patients](https://reader036.fdocuments.us/reader036/viewer/2022062602/5ed3ee7ab385103868573c1b/html5/thumbnails/23.jpg)
G Parenti et al. Int J Mol Med. 2013; 31: 11-20.
Rational Therapeutic Targets for NCLs
![Page 24: The Past, Present, and Future of Rare Disease Trials · 12-year UK epidemiologicstudyofPIND,147differentdiagnoseswererecordedin 1114 of 2636patients](https://reader036.fdocuments.us/reader036/viewer/2022062602/5ed3ee7ab385103868573c1b/html5/thumbnails/24.jpg)
Clinical Presentation Of CLN2 Disease/TPP1 Deficiency
Adapted from: Kohlschütter A. Pediatr Endocrinol Rev 2016
Birth 4 5 6 7 8 12
Age (years)
1 2 3
Early features (2-4 years):
• Early language delay• Seizures, often polymorphic• Increasing developmental
concerns• Referral for diagnostic
investigations• Developmental stasis
Rapidly Progressing (3-5 years):
• Drug-resistant seizures• Loss of milestones• Progressive dementia• Movement disorder• Sleep disorder• Worsening mobility• Pain and irritability
9 10 11
Prolonged Late stage :
• Gastrostomy dependent• Dysphagia• Loss of communication• Loss of voluntary movement
• Ongoing seizures and myoclonus
• Spasticity, contractures
![Page 25: The Past, Present, and Future of Rare Disease Trials · 12-year UK epidemiologicstudyofPIND,147differentdiagnoseswererecordedin 1114 of 2636patients](https://reader036.fdocuments.us/reader036/viewer/2022062602/5ed3ee7ab385103868573c1b/html5/thumbnails/25.jpg)
Schulz et al., 2018
Motor & language function scoring (CLN2)
![Page 26: The Past, Present, and Future of Rare Disease Trials · 12-year UK epidemiologicstudyofPIND,147differentdiagnoseswererecordedin 1114 of 2636patients](https://reader036.fdocuments.us/reader036/viewer/2022062602/5ed3ee7ab385103868573c1b/html5/thumbnails/26.jpg)
CLN2 Natural History
0
1
2
3
4
5
6
0 24 48 72 168 192
Sum
of m
oto
r and
language s
co
re
96 120 144
Age, Months
10% 25%75% 90%
First seizure:~2.9 years
Walking: Normal
Language: Minor concerns
Age at diagnosis: ~5 years
No independent walking
Language: Unintelligible
Rate of
decline
2.2 units/year
(SD±1.1)
N=58 subjects with CLN2 disease in the DEM-CHILD registry, a multinational NCL patient database.
Nickel M, et al. Europ J Paed Neuro 2015 PP03.8 –2898.
![Page 27: The Past, Present, and Future of Rare Disease Trials · 12-year UK epidemiologicstudyofPIND,147differentdiagnoseswererecordedin 1114 of 2636patients](https://reader036.fdocuments.us/reader036/viewer/2022062602/5ed3ee7ab385103868573c1b/html5/thumbnails/27.jpg)
Cerliponase alfa – approved for prevention of loss of ambulation in CLN2 disease (2017)
A Schulz, et al. NEJM 2018.
![Page 28: The Past, Present, and Future of Rare Disease Trials · 12-year UK epidemiologicstudyofPIND,147differentdiagnoseswererecordedin 1114 of 2636patients](https://reader036.fdocuments.us/reader036/viewer/2022062602/5ed3ee7ab385103868573c1b/html5/thumbnails/28.jpg)
Spinal Muscular Atrophy (SMA)Leading Genetic Cause of Infant Mortality
Neurol Clin 33 (2015) 831–846
![Page 29: The Past, Present, and Future of Rare Disease Trials · 12-year UK epidemiologicstudyofPIND,147differentdiagnoseswererecordedin 1114 of 2636patients](https://reader036.fdocuments.us/reader036/viewer/2022062602/5ed3ee7ab385103868573c1b/html5/thumbnails/29.jpg)
Spinal Muscular Atrophy Timeline
SJ Kolb and JT Kissel. Archives of neurology 68 8 (2011): 979-84 .
![Page 30: The Past, Present, and Future of Rare Disease Trials · 12-year UK epidemiologicstudyofPIND,147differentdiagnoseswererecordedin 1114 of 2636patients](https://reader036.fdocuments.us/reader036/viewer/2022062602/5ed3ee7ab385103868573c1b/html5/thumbnails/30.jpg)
2017: 1st treatment for Spinal Muscular Atrophy
N Engl J Med 2017;377:1723-32.
![Page 31: The Past, Present, and Future of Rare Disease Trials · 12-year UK epidemiologicstudyofPIND,147differentdiagnoseswererecordedin 1114 of 2636patients](https://reader036.fdocuments.us/reader036/viewer/2022062602/5ed3ee7ab385103868573c1b/html5/thumbnails/31.jpg)
Nusinersen impacts survival for patients with SMA
N Engl J Med 2017;377:1723-32.
![Page 32: The Past, Present, and Future of Rare Disease Trials · 12-year UK epidemiologicstudyofPIND,147differentdiagnoseswererecordedin 1114 of 2636patients](https://reader036.fdocuments.us/reader036/viewer/2022062602/5ed3ee7ab385103868573c1b/html5/thumbnails/32.jpg)
Gene replacement therapy for SMA (2019)
N Engl J Med 2017;377:1713-22.
![Page 33: The Past, Present, and Future of Rare Disease Trials · 12-year UK epidemiologicstudyofPIND,147differentdiagnoseswererecordedin 1114 of 2636patients](https://reader036.fdocuments.us/reader036/viewer/2022062602/5ed3ee7ab385103868573c1b/html5/thumbnails/33.jpg)
PRESENT: Translating knowledge to treatment
33
![Page 34: The Past, Present, and Future of Rare Disease Trials · 12-year UK epidemiologicstudyofPIND,147differentdiagnoseswererecordedin 1114 of 2636patients](https://reader036.fdocuments.us/reader036/viewer/2022062602/5ed3ee7ab385103868573c1b/html5/thumbnails/34.jpg)
PRESENTDescribing phenomenology, grouping characteristics, linking to genetic diagnosis, accelerating development of new therapies
![Page 35: The Past, Present, and Future of Rare Disease Trials · 12-year UK epidemiologicstudyofPIND,147differentdiagnoseswererecordedin 1114 of 2636patients](https://reader036.fdocuments.us/reader036/viewer/2022062602/5ed3ee7ab385103868573c1b/html5/thumbnails/35.jpg)
FUTURE
![Page 36: The Past, Present, and Future of Rare Disease Trials · 12-year UK epidemiologicstudyofPIND,147differentdiagnoseswererecordedin 1114 of 2636patients](https://reader036.fdocuments.us/reader036/viewer/2022062602/5ed3ee7ab385103868573c1b/html5/thumbnails/36.jpg)
Rising Interest in Therapy Development for NCLs
Pre-clinical models
Clinician-Investigators Successful product approval
Regulatory incentivesEngaged families &
foundationsNatural history
knowledge
36
![Page 37: The Past, Present, and Future of Rare Disease Trials · 12-year UK epidemiologicstudyofPIND,147differentdiagnoseswererecordedin 1114 of 2636patients](https://reader036.fdocuments.us/reader036/viewer/2022062602/5ed3ee7ab385103868573c1b/html5/thumbnails/37.jpg)
RD Geraets, et al. Orphanet Journal of Rare Diseasesvolume 11, Article number: 40 (2016) 37
![Page 38: The Past, Present, and Future of Rare Disease Trials · 12-year UK epidemiologicstudyofPIND,147differentdiagnoseswererecordedin 1114 of 2636patients](https://reader036.fdocuments.us/reader036/viewer/2022062602/5ed3ee7ab385103868573c1b/html5/thumbnails/38.jpg)
Small molecule approaches
CLN1, CLN3
Gene replacement therapies (AAV9, various routes of administration)
CLN1, CLN2, CLN3, CLN5, CLN6, CLN7
Enzyme replacement
CLN1
Anti-sense oligonucleotide therapy
CLN7
NCL Therapeutic Pipeline
![Page 39: The Past, Present, and Future of Rare Disease Trials · 12-year UK epidemiologicstudyofPIND,147differentdiagnoseswererecordedin 1114 of 2636patients](https://reader036.fdocuments.us/reader036/viewer/2022062602/5ed3ee7ab385103868573c1b/html5/thumbnails/39.jpg)
Emerging Therapeutic Strategies
http://www.sens.orghttp://www.sens.org
![Page 40: The Past, Present, and Future of Rare Disease Trials · 12-year UK epidemiologicstudyofPIND,147differentdiagnoseswererecordedin 1114 of 2636patients](https://reader036.fdocuments.us/reader036/viewer/2022062602/5ed3ee7ab385103868573c1b/html5/thumbnails/40.jpg)
Emerging Therapeutic Strategies
http://www.sens.orgEG Shapiro, et al 1994; http://www.sens.org
Disease modification (development)
Intellectual
Disability
![Page 41: The Past, Present, and Future of Rare Disease Trials · 12-year UK epidemiologicstudyofPIND,147differentdiagnoseswererecordedin 1114 of 2636patients](https://reader036.fdocuments.us/reader036/viewer/2022062602/5ed3ee7ab385103868573c1b/html5/thumbnails/41.jpg)
Paciorkowski, et al. CONTINUUM. 2018;24(1):18–36.
![Page 42: The Past, Present, and Future of Rare Disease Trials · 12-year UK epidemiologicstudyofPIND,147differentdiagnoseswererecordedin 1114 of 2636patients](https://reader036.fdocuments.us/reader036/viewer/2022062602/5ed3ee7ab385103868573c1b/html5/thumbnails/42.jpg)
Paciorkowski, et al. CONTINUUM. 2018;24(1):18–36.
Genetic Heterogeneity Phenotypic Pleiotropy
![Page 43: The Past, Present, and Future of Rare Disease Trials · 12-year UK epidemiologicstudyofPIND,147differentdiagnoseswererecordedin 1114 of 2636patients](https://reader036.fdocuments.us/reader036/viewer/2022062602/5ed3ee7ab385103868573c1b/html5/thumbnails/43.jpg)
Increasing recognition of links between rare and common disorders
• NCL and frontotemporal dementia• Rare and common epilepsies• Lysosomal storage disease and Parkinson Disease Lancet Neurol. 2017; 16: 135–143
Ward, et al. Science Translational Med. 2017; 9(385): eaah5642
![Page 44: The Past, Present, and Future of Rare Disease Trials · 12-year UK epidemiologicstudyofPIND,147differentdiagnoseswererecordedin 1114 of 2636patients](https://reader036.fdocuments.us/reader036/viewer/2022062602/5ed3ee7ab385103868573c1b/html5/thumbnails/44.jpg)
Source: FDA Law Blog; Vermillion et al 2018
Pediatric approvals may be on the decline
+Pediatric
7% annual decline (95%CI -9.8,-4.1) p<0.0001
-Pediatric Total
![Page 45: The Past, Present, and Future of Rare Disease Trials · 12-year UK epidemiologicstudyofPIND,147differentdiagnoseswererecordedin 1114 of 2636patients](https://reader036.fdocuments.us/reader036/viewer/2022062602/5ed3ee7ab385103868573c1b/html5/thumbnails/45.jpg)
• Efficient diagnosis and recognition of disease
• Incomplete understanding of natural history
• Lack of robust, patient-relevant outcome measures
• Low statistical power for small sample sizes
• Challenges in recruitment
• Late phase compound failures
Augustine, et al. J Child Neurol 2013deBlieck, Augustine, et al. Contemp Clin Trials 2013
Rare Disease Barriers to Therapy Development
![Page 46: The Past, Present, and Future of Rare Disease Trials · 12-year UK epidemiologicstudyofPIND,147differentdiagnoseswererecordedin 1114 of 2636patients](https://reader036.fdocuments.us/reader036/viewer/2022062602/5ed3ee7ab385103868573c1b/html5/thumbnails/46.jpg)
• Impact on lifespan, other key disease domains
• Emergence of systemic pathology
• Long-term tolerability and device duration
• Delivery optimization
• Need for combination approaches
• Development of robust global disease endpoints
Emerging Questions – CLN2 disease
![Page 47: The Past, Present, and Future of Rare Disease Trials · 12-year UK epidemiologicstudyofPIND,147differentdiagnoseswererecordedin 1114 of 2636patients](https://reader036.fdocuments.us/reader036/viewer/2022062602/5ed3ee7ab385103868573c1b/html5/thumbnails/47.jpg)
• Relative importance of gene expression level versus cell specificity
• Adequacy of preclinical model translation to human benefit
• Threshold age of intervention
• Add-on therapy considerations
• Competing trials in a small population
Translational and trial design considerations
47
![Page 48: The Past, Present, and Future of Rare Disease Trials · 12-year UK epidemiologicstudyofPIND,147differentdiagnoseswererecordedin 1114 of 2636patients](https://reader036.fdocuments.us/reader036/viewer/2022062602/5ed3ee7ab385103868573c1b/html5/thumbnails/48.jpg)
Challenges ahead
Clin Transl Sci. 2018 Jan; 11(1): 21–27
• Timely diagnosis for known disorders
• Defining unsolved diseases
• Approved treatments with quality data
• Treatment access
• Increasing total # of treatments
• Increasing rate of first treatments
• Future of the Orphan Drug Act
![Page 49: The Past, Present, and Future of Rare Disease Trials · 12-year UK epidemiologicstudyofPIND,147differentdiagnoseswererecordedin 1114 of 2636patients](https://reader036.fdocuments.us/reader036/viewer/2022062602/5ed3ee7ab385103868573c1b/html5/thumbnails/49.jpg)
Cost and equity
49
![Page 50: The Past, Present, and Future of Rare Disease Trials · 12-year UK epidemiologicstudyofPIND,147differentdiagnoseswererecordedin 1114 of 2636patients](https://reader036.fdocuments.us/reader036/viewer/2022062602/5ed3ee7ab385103868573c1b/html5/thumbnails/50.jpg)
Cost and equity
50
![Page 51: The Past, Present, and Future of Rare Disease Trials · 12-year UK epidemiologicstudyofPIND,147differentdiagnoseswererecordedin 1114 of 2636patients](https://reader036.fdocuments.us/reader036/viewer/2022062602/5ed3ee7ab385103868573c1b/html5/thumbnails/51.jpg)
Cost and equity
51
![Page 52: The Past, Present, and Future of Rare Disease Trials · 12-year UK epidemiologicstudyofPIND,147differentdiagnoseswererecordedin 1114 of 2636patients](https://reader036.fdocuments.us/reader036/viewer/2022062602/5ed3ee7ab385103868573c1b/html5/thumbnails/52.jpg)
FUTUREAccelerating development of new therapies, defining precise and meaningful diagnosis, changing our concept of therapeutic treatment groups, early and multi-modal intervention
![Page 53: The Past, Present, and Future of Rare Disease Trials · 12-year UK epidemiologicstudyofPIND,147differentdiagnoseswererecordedin 1114 of 2636patients](https://reader036.fdocuments.us/reader036/viewer/2022062602/5ed3ee7ab385103868573c1b/html5/thumbnails/53.jpg)
The Road Ahead
53
![Page 54: The Past, Present, and Future of Rare Disease Trials · 12-year UK epidemiologicstudyofPIND,147differentdiagnoseswererecordedin 1114 of 2636patients](https://reader036.fdocuments.us/reader036/viewer/2022062602/5ed3ee7ab385103868573c1b/html5/thumbnails/54.jpg)
Systematically building clinical knowledge about rare diseases
Sequencing Symptom Onset Quantifying Progression Examining Sex Differences
54https://www.urmc.rochester.edu/neurology/batten-disease-center.aspx
Neuronal Ceroid Lipofuscinoses (Batten diseases)
![Page 55: The Past, Present, and Future of Rare Disease Trials · 12-year UK epidemiologicstudyofPIND,147differentdiagnoseswererecordedin 1114 of 2636patients](https://reader036.fdocuments.us/reader036/viewer/2022062602/5ed3ee7ab385103868573c1b/html5/thumbnails/55.jpg)
Modeling Disease Trajectory Clinical Endpoint & Biomarker Qualification
Testing Novel Interventions
Next Steps – Batten Diseases
Brain image courtesy A.Schulz
![Page 56: The Past, Present, and Future of Rare Disease Trials · 12-year UK epidemiologicstudyofPIND,147differentdiagnoseswererecordedin 1114 of 2636patients](https://reader036.fdocuments.us/reader036/viewer/2022062602/5ed3ee7ab385103868573c1b/html5/thumbnails/56.jpg)
56
www.trnds.org – September 19, 2019
![Page 57: The Past, Present, and Future of Rare Disease Trials · 12-year UK epidemiologicstudyofPIND,147differentdiagnoseswererecordedin 1114 of 2636patients](https://reader036.fdocuments.us/reader036/viewer/2022062602/5ed3ee7ab385103868573c1b/html5/thumbnails/57.jpg)
Research Funding: NIH/NINDS, Batten Disease Support and Research Association, Batten Research Alliance, Abeona Therapeutics
Consultant: BioMarin Pharmaceutical, Regenxbio, Beyond Batten Disease Foundation
Batten Research Group & CollaboratorsJonathan Mink Foxe LabFrederick Marshall Singh LabHeather Adams Weimer LabAmy Vierhile Gray LabChristopher Beck Giovanni SchifittoAlyssa Thatcher Jen VermilionKris Bonafacio Shannon DeanGrace Zimmerman Mina Chung